Pharma BD Deal Intelligence

Treeline Biosciences, Inc. / Roche Holding AG

2026 · Co-Development · Complete

Treeline Biosciences and Roche entered a clinical trial collaboration and supply agreement to evaluate Treeline's BCL6 degrader TLN-121 in combination with Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in B-cell lymphoma. Treeline sponsors and oversees the Phase 1 dose-escalation and expansion study; Roche supplies glofitamab and mosunetuzumab for the designated combination expansion cohorts, evaluated in separate arms including diffuse large B-cell lymphoma. Combination dosing is intended to begin in Q4 2026. No financial terms were disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals